On May 19, 2016 Clovis Oncology, Inc. (NASDAQ: CLVS) reported its presence at the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, where it will share updated results from clinical studies of rucaparib (Press release, Clovis Oncology, MAY 19, 2016, View Source;p=irol-newsArticle_Print&ID=2170005 [SID:1234512606]). ASCO (Free ASCO Whitepaper) will take place June 3-7, 2016 in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to providing updates on rucaparib data in ovarian cancer, including in patients with mutations beyond BRCA, as well as the first presentation of our pancreatic cancer data," said Patrick J. Mahaffy, CEO and President of Clovis Oncology. "These datasets demonstrate rucaparib’s encouraging clinical activity and tolerability profile in the treatment of ovarian and pancreatic cancers. Both represent diseases in which BRCA mutations play a significant role in certain patients, as well as areas where additional treatment options are very much needed."

Rucaparib is the Company’s oral, potent, small molecule inhibitor of PARP1-3 currently being developed for the treatment of ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, including those with high genomic loss of heterozygosity (LOH) commonly referred to as "BRCA-like." Data from rucaparib studies are the subject of three poster presentations at the conference:

Abstract 4110 – RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.

Susan M. Domchek, MD, University of Pennsylvania, Philadelphia, PA
Saturday, June 4 from 8:00am-11:30am CDT
Location: Hall A, Poster Board #102
Abstract 5540 – Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).

Robert L. Coleman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
Monday, June 6 from 1:00pm-4:30pm CDT
Location: Hall A, Poster Board #363
Abstract 5549 – Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade serous carcinoma on the ARIEL2 trial.

Anna Piskorz, PhD, Cancer Research UK Cambridge Institute, University of Cambridge
Monday, June 6 from 1:00pm-4:30pm CDT
Location: Hall A, Poster Board #372
About Rucaparib

Rucaparib is an oral, potent small molecule inhibitor of PARP1-3 being developed for the treatment of ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, including those with high genomic loss of heterozygosity (LOH) commonly referred to as "BRCA-like." Clovis is also exploring rucaparib in other solid tumor types with significant BRCA and BRCA-like populations, including prostate, breast and gastroesophageal cancers. Rucaparib was granted Breakthrough Therapy designation by the U.S. FDA in April 2015. Clovis holds worldwide rights for rucaparib.